A. Oliver Sartor, MD
Radiopharmaceuticals could be part of the next wave of progress in prostate cancer treatment, pending a phase III trial evaluating efficacy with lutetium-177 PSMA-617 (Lu-PSMA-617) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC), explained A. Oliver Sartor, MD.
... to read the full story
Comments
Post a Comment